MedTrace Logo

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714661 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 753

Last updated 2016-05-03

No results posted yet for this study

Summary

The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.

Conditions

Interventions

DRUG

EVP-6124

Arms 1, 2

DRUG

Placebo

Arm 3

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • NeuroCog Trials, Inc.

    collaborator INDUSTRY

  • FORUM Pharmaceuticals Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada
  • Germany
  • Mexico
  • Poland
  • Russia
  • Serbia
  • Singapore
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01714661 on ClinicalTrials.gov